An in-depth look at the emerging GLP-1/GIP/Glucagon receptor triple agonist compound and its role in metabolic research
Explore Research CatalogA synthetic peptide analog investigational compound under study for its multi-receptor activity across three distinct metabolic signaling pathways.
Retatrutide, research designation LY3437943, is a synthetic peptide investigational compound developed by Eli Lilly and Company. It is classified as a unimolecular triagonist — a single molecule engineered to engage three separate G protein-coupled receptors simultaneously.
Unlike mono-agonist or dual-agonist peptides, retatrutide is designed to activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR) within a single molecular scaffold.
The compound is administered via once-weekly subcutaneous injection in clinical research settings. It is formulated for research-model and clinical investigation purposes and is not approved for human use outside of regulated clinical trial contexts.
The development of multi-receptor agonist peptides represents a significant area of inquiry within metabolic and endocrinological research. By engaging multiple receptor pathways simultaneously, researchers seek to understand synergistic effects on energy homeostasis, insulin secretion, and hepatic glucose production that are not achievable through single-receptor targeting alone.
Retatrutide's triple-agonist profile positions it as a pharmacological research tool of considerable scientific interest. Its progression through Phase 1 and Phase 2 clinical evaluation has generated a substantial body of peer-reviewed data examining receptor pharmacology, dose-response relationships, and safety characterization in human subjects within controlled trial conditions.
Activation of the glucagon-like peptide-1 receptor promotes glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and modulates central appetite signaling via hypothalamic pathways. GLP-1 receptor agonism is the most extensively characterized receptor mechanism in this class of peptides and forms the pharmacological backbone of retatrutide's activity profile.
The glucose-dependent insulinotropic polypeptide receptor plays a complementary insulinotropic role and is implicated in adipose tissue lipid metabolism and energy storage regulation. Co-agonism at both GLP-1 and GIP receptors is hypothesized to produce additive or synergistic effects on insulin secretion and energy balance, a mechanism explored in research models and now validated in clinical Phase 2 data with tirzepatide and, with the third receptor added, retatrutide.
Inclusion of glucagon receptor agonism is the distinguishing feature that separates retatrutide from dual agonists. Glucagon receptor activation is associated with increased hepatic glucose production, thermogenic effects via brown adipose tissue stimulation, and elevated energy expenditure. In research models, the combination of glucagon receptor agonism with GLP-1 and GIP agonism is studied for its potential to augment caloric expenditure beyond what appetite suppression alone can achieve — making it a mechanistically novel tool in metabolic research.
Published data from the Phase 2 randomized controlled trial (Jastreboff AM et al., NEJM 2023) characterizes retatrutide's dose-dependent profile across multiple metabolic parameters.
Understanding retatrutide's position within the GLP-1 class requires comparing it to established mono- and dual-agonist compounds across receptor engagement and published trial profiles.
Semaglutide is a GLP-1 receptor mono-agonist with 94% sequence homology to native GLP-1 and an extended half-life via fatty acid conjugation enabling once-weekly dosing. In Phase 3 trials (STEP program), semaglutide 2.4 mg demonstrated approximately 14.9% mean body weight reduction at 68 weeks. Its mechanism is limited to the GLP-1 receptor pathway, encompassing insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite modulation. It does not engage the GIP or glucagon receptors and therefore lacks the complementary and thermogenic receptor activities present in dual and triple agonists. It represents the pharmacological foundation on which subsequent multi-receptor compounds were built.
Tirzepatide is a GLP-1/GIP dual receptor agonist — a "twincretin" — that engages both the GLP-1 and GIP receptors within a single peptide scaffold. In Phase 3 trials (SURMOUNT program), tirzepatide 15 mg demonstrated approximately 20.9% mean body weight reduction at 72 weeks, representing a meaningful advance over GLP-1 mono-agonism. The addition of GIP receptor agonism is hypothesized to enhance insulinotropic response and favorably modulate adipose tissue metabolism. Tirzepatide does not engage the glucagon receptor, and therefore does not incorporate the thermogenic and hepatic energy expenditure-promoting effects that are theorized to contribute to retatrutide's distinct efficacy profile in clinical research.
Retatrutide extends beyond both mono- and dual-agonist compounds by incorporating glucagon receptor agonism as a third simultaneous signaling pathway. This triple-receptor engagement distinguishes it pharmacologically: the glucagon receptor component introduces a thermogenic dimension via brown adipose tissue activation and increased hepatic energy expenditure that is absent in both semaglutide and tirzepatide. Published Phase 2 data demonstrate a 24.2% mean body weight reduction at 48 weeks in the 12 mg cohort — a magnitude not previously observed in this class at this timepoint. The additive or synergistic effects of engaging three complementary metabolic receptor axes simultaneously represent the defining scientific question driving ongoing Phase 3 (TRIUMPH program) investigation.
Frequently asked scientific questions about retatrutide's pharmacology, clinical data, development status, and research access.
Retatrutide (LY3437943) is a unimolecular triple receptor agonist that simultaneously engages three G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Each receptor represents a distinct signaling pathway involved in metabolic regulation. GLP-1R agonism drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and modulates appetite signaling centrally. GIPR agonism provides a complementary insulinotropic effect and is implicated in adipose tissue energy storage modulation. GCGR agonism activates hepatic glucose production pathways and promotes thermogenesis via brown adipose tissue, contributing increased energy expenditure on top of appetite-suppressive mechanisms. The integration of all three within a single peptide scaffold is the core pharmacological innovation of retatrutide relative to predecessor compounds in the GLP-1 therapeutic class.
The Phase 2 data for retatrutide were published by Jastreboff AM et al. in the New England Journal of Medicine (2023, DOI: 10.1056/NEJMoa2301972). The randomized, double-blind, placebo-controlled trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were assigned to one of six active dose cohorts (1 mg, 2 mg, 4 mg, 8 mg, 12 mg with dose escalation, or 12 mg fixed) or placebo, administered via once-weekly subcutaneous injection over 48 weeks. The primary endpoint was mean percent change in body weight from baseline to week 48. In the 12 mg escalation cohort, mean body weight reduction reached 24.2% — statistically significant versus placebo (p<0.001). All active dose cohorts achieved statistically significant separation from placebo. The 8 mg cohort demonstrated approximately 17% mean reduction. The safety profile was characterized primarily by gastrointestinal adverse events (nausea, vomiting, diarrhea) consistent with GLP-1 class effects, generally dose-dependent and transient. These results supported advancement to Phase 3 evaluation.
The primary pharmacological distinction is receptor breadth. Semaglutide is a GLP-1 receptor mono-agonist engaging one receptor pathway; tirzepatide is a GLP-1/GIP dual receptor agonist engaging two; retatrutide is a GLP-1/GIP/Glucagon triple receptor agonist engaging three simultaneously within a single molecular structure. The incremental addition of GIP receptor agonism (tirzepatide over semaglutide) demonstrated an approximate 6 percentage point increase in mean body weight reduction in Phase 3 vs Phase 3 comparisons. The further addition of glucagon receptor agonism in retatrutide introduces a thermogenic energy expenditure component via brown adipose tissue and hepatic pathways that is absent in both predecessor compounds. Published Phase 2 data for retatrutide show approximately 24.2% mean body weight reduction at 48 weeks (12 mg cohort), compared to approximately 14.9% for semaglutide at 68 weeks (STEP 1) and approximately 20.9% for tirzepatide at 72 weeks (SURMOUNT-1). Direct head-to-head trials have not been published; cross-trial comparisons are confounded by differing trial designs, populations, and durations, and should be interpreted with appropriate scientific caution.
As of 2024, retatrutide has completed Phase 2 clinical evaluation and has advanced into Phase 3 investigation under the TRIUMPH clinical trial program, conducted by Eli Lilly and Company. Phase 3 trials are designed to evaluate efficacy and long-term safety across larger and more diverse populations than Phase 2, and typically include trials examining cardiovascular outcomes, effects in type 2 diabetes, and additional comorbidity-specific cohorts. Retatrutide does not currently hold regulatory approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other major regulatory bodies for any indication. It remains an investigational compound. Access outside of regulated clinical trial participation is limited to licensed research contexts, and any use of retatrutide outside of authorized research settings is inconsistent with its current regulatory status. Researchers should monitor Eli Lilly's official clinical communications and ClinicalTrials.gov for current trial enrollment status and published updates.
Researchers seeking access to retatrutide for laboratory or preclinical study purposes may source it through licensed peptide research suppliers. These suppliers produce synthetic retatrutide for in vitro and in vivo non-clinical research use, strictly in compliance with applicable regulations. Research-grade peptide compounds are supplied exclusively for use in qualified research settings by credentialed investigators and are not for human administration outside of regulated clinical trials. Institutional researchers conducting in vitro studies, receptor binding assays, animal model research, or mechanistic pharmacology investigations may procure retatrutide through appropriate research supply channels with valid institutional credentials. RetakingResearch.com provides a curated catalog of research compounds for qualified research purposes. All compounds listed are sold strictly for research purposes only and are not for human consumption.
RetakingResearch.com maintains a curated catalog of research-grade peptide compounds for qualified researchers and research institutions.
View Available Research CompoundsAll compounds are supplied strictly for research purposes only and are not intended for human consumption. Access is intended for credentialed researchers, research institutions, and qualified scientific investigators operating within applicable legal and regulatory frameworks.